Evotec (EVO) Competitors

Nuvalent (NASDAQ:NUVL) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, community ranking, valuation, earnings and profitability.

Is NUVL or EVO more profitable?

Evotec's return on equity of 0.00% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-28.63%	-27.15%
Evotec	N/A	N/A	N/A

Do analysts rate NUVL or EVO?

Nuvalent currently has a consensus target price of $115.50, indicating a potential upside of 47.62%. Evotec has a consensus target price of $5.93, indicating a potential upside of 38.95%. Given Nuvalent's stronger consensus rating and higher probable upside, equities analysts plainly believe Nuvalent is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Evotec	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Which has more risk and volatility, NUVL or EVO?

Nuvalent has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.

Does the media refer more to NUVL or EVO?

In the previous week, Nuvalent had 4 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Nuvalent and 2 mentions for Evotec. Evotec's average media sentiment score of 1.52 beat Nuvalent's score of 0.90 indicating that Evotec is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Does the MarketBeat Community favor NUVL or EVO?

Nuvalent received 38 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 77.59% of users gave Nuvalent an outperform vote while only 53.85% of users gave Evotec an outperform vote.

Company	Underperform	Outperform
Nuvalent	Outperform Votes 45 77.59%	Underperform Votes 13 22.41%
Evotec	Outperform Votes 7 53.85%	Underperform Votes 6 46.15%

Do institutionals & insiders have more ownership in NUVL or EVO?

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 10.2% of Nuvalent shares are held by company insiders. Comparatively, 1.0% of Evotec shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has better valuation & earnings, NUVL or EVO?

Evotec has higher revenue and earnings than Nuvalent.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$126.22M	-$4.39	-17.82
Evotec	$788.22M	1.92	-$90.82M	N/A	N/A

Summary

Nuvalent beats Evotec on 9 of the 15 factors compared between the two stocks.